First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW

被引：0

作者：

Kang, Y-K. ^{[1
]}

Shah, M. A. ^{[2
]}

Shitara, K. ^{[3
]}

Ajani, J. A. ^{[4
]}

Lordick, F. ^{[5
]}

Van Cutsem, E. ^{[6
]}

Ilson, D. H. ^{[7
]}

Klempner, S. J. ^{[8
]}

Yamaguchi, K. ^{[9
]}

Nakajima, T. ^{[10
]}

Cao, Y. J. ^{[11
]}

Li, R. ^{[12
]}

Moran, D. ^{[11
]}

Pophale, R. R. ^{[13
]}

Ranganath, R. ^{[13
]}

Xu, R-H. ^{[14
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[2] Weill Cornell Med Coll, Med Oncol & Hematol Dept, New York, NY USA

[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[4] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

[5] Univ Krebszentrum Leipzig, Univ Klinikum Leipzig, Med Dept, Leipzig, Germany

[6] UZ Leuven, Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium

[7] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[8] MGH Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA

[9] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan

[10] Astellas Pharma Global Dev, Med Dept, Northbrook, IL USA

[11] Astellas Pharma Global Dev Inc, Data Sci, Northbrook, IL USA

[12] Astellas Pharma Global Dev, Data Sci, Northbrook, IL USA

[13] Astellas Pharma Global Dev Inc, Med Affairs Dept, Northbrook, IL USA

[14] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1438P

引用

页码：S895 / S895

页数：1

共 50 条

[21] SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Lordick, F.
Shitara, K.
Al-Batran, S. -E
Bang, Y. -J
Catenacci, D.
Enzinger, P.
Ilson, D.
Kim, S.
Shah, M. A.
Van Cutsem, E.
Xu, R. -H
Arozullah, A.
Park, J. W.
Ajani, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
[22] SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Shitara, K.
Al-Batran, S-E.
Bang, Y-J.
Catenacci, D.
Enzinger, P. C.
Ilson, D. H.
Kim, S.
Lordick, F.
Shah, M. A.
van Cutsem, E.
Xu, R-H.
Arozullah, A.
Park, J. W.
Ajani, J. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1317 - S1317
[23] First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
Lei, Jianying
Zhang, Jiahao
You, Caicong
Fu, Wu
Liu, Maobai
Li, Na
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
[24] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Xu, Rui-hua
Arkenau, Hendrik-Tobias
Bang, Yung-Jue
Denlinger, Crystal S.
Kato, Ken
Tabernero, Josep
Wang, Jin
Li, Jiang
Castro, Henry
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[25] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3.
Klempner, Samuel J.
Ajani, Jaffer A.
Al-Batran, Salah-Eddin
Bang, Yung-Jue
Catenacci, Daniel V. T.
Enzinger, Peter C.
Ilson, David H.
Kim, Sunnie
Lordick, Florian
Shah, Manish A.
Shitara, Kohei
Arozullah, Ahsan
Park, Jung Wook
Raizer, Jeffrey J.
Van Cutsem, Eric
Xu Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[26] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Liu, Funan
Gong, Jifang
Jin, Zhaoyu
Zhang, Miao
Zhang, Shu
Zhang, Yanqiao
Liang, Xinjun
Li, Yun
Yang, Xiaochun
Yang, Yaping
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).
Lee, Keun-Wook
Klempner, Samuel J.
Yang, Jianning
Desai, Amit
Yamada, Akihiro
Ueno, Yoko
Wojtkowski, Tomasz
Park, Jung Wook
Pavese, Janet
Loupakis, Fotios
Bang, Yung-Jue
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
Klempner, Samuel J.
Lee, Keun-Wook
Metges, Jean-Philippe
Catenacci, Daniel V. T.
Loupakis, Fotios
Ilson, David H.
Shah, Manish A.
Shitara, Kohei
Arozullah, Ahsan
Park, Jung Wook
Raizer, Jeffrey J.
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Health-related quality of life (hrqol) in patients with claudin18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and
Lordick, F.
Van Cutsem, E.
Shitara, K.
Xu, R-H.
Ajani, J. A.
Shah, M. A.
Oh, M.
Ganguli, A.
Rhoten, S.
Bhattacharya, P.
Matsangou, M.
Park, J. W.
Kang, Y-K.
ANNALS OF ONCOLOGY, 2023, 34 : S860 - S861
[30] A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2-advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Gong, J.
Liu, F.
Jin, Z.
Zhang, M.
Zhang, S.
Zhang, Y.
Liang, X.
Li, Y.
Yang, Y.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S892 - S892

← 1 2 3 4 5 →